Descotes F - Search Results

1

Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers.

David M, Sahay D, Mege F, Descotes F, Leblanc R, Ribeiro J, Clézardin P, Peyruchaud O. David M, et al. Among authors: descotes f. PLoS One. 2014 May 14;9(5):e97771. doi: 10.1371/journal.pone.0097771. eCollection 2014. PLoS One. 2014. PMID: 24828490 Free PMC article.

2

Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts.

David M, Wannecq E, Descotes F, Jansen S, Deux B, Ribeiro J, Serre CM, Grès S, Bendriss-Vermare N, Bollen M, Saez S, Aoki J, Saulnier-Blache JS, Clézardin P, Peyruchaud O. David M, et al. Among authors: descotes f. PLoS One. 2010 Mar 17;5(3):e9741. doi: 10.1371/journal.pone.0009741. PLoS One. 2010. PMID: 20305819 Free PMC article.

3

Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis.

David M, Ribeiro J, Descotes F, Serre CM, Barbier M, Murone M, Clézardin P, Peyruchaud O. David M, et al. Among authors: descotes f. Int J Oncol. 2012 Apr;40(4):1133-41. doi: 10.3892/ijo.2011.1309. Epub 2011 Dec 20. Int J Oncol. 2012. PMID: 22200658 Free PMC article.

4

Dual function of ERRα in breast cancer and bone metastasis formation: implication of VEGF and osteoprotegerin.

Fradet A, Sorel H, Bouazza L, Goehrig D, Dépalle B, Bellahcène A, Castronovo V, Follet H, Descotes F, Aubin JE, Clézardin P, Bonnelye E. Fradet A, et al. Among authors: descotes f. Cancer Res. 2011 Sep 1;71(17):5728-38. doi: 10.1158/0008-5472.CAN-11-1431. Epub 2011 Jul 6. Cancer Res. 2011. PMID: 21734015 Free article.

5

miRNA-30 Family Members Inhibit Breast Cancer Invasion, Osteomimicry, and Bone Destruction by Directly Targeting Multiple Bone Metastasis-Associated Genes.

Croset M, Pantano F, Kan CWS, Bonnelye E, Descotes F, Alix-Panabières C, Lecellier CH, Bachelier R, Allioli N, Hong SS, Bartkowiak K, Pantel K, Clézardin P. Croset M, et al. Among authors: descotes f. Cancer Res. 2018 Sep 15;78(18):5259-5273. doi: 10.1158/0008-5472.CAN-17-3058. Epub 2018 Jul 24. Cancer Res. 2018. PMID: 30042152 Free article.

6

Identification of potential prognostic biomarkers for node-negative breast tumours by proteomic analysis: a multicentric 2004 national PHRC study.

Descotes F, Jézéquel P, Spyratos F, Campion L, Grenot C, Lerebours F, Campone M, Guérin-Charbonnel C, Lanoë D, Adams M, André J, Carlioz A, Martin PM, Chassevent A, Jourdan ML, Guette C, Zanella-Cleon I, Ricolleau G. Descotes F, et al. Int J Oncol. 2012 Jul;41(1):92-104. doi: 10.3892/ijo.2012.1456. Epub 2012 Apr 30. Int J Oncol. 2012. PMID: 22552268 Free article.

7

Divergent biological effects of estradiol and diethylstilbestrol in the prostate cancer cell line MOP.

Kalach JJ, Joly-Pharaboz MO, Chantepie J, Nicolas B, Descotes F, Mauduit C, Benahmed M, André J. Kalach JJ, et al. Among authors: descotes f. J Steroid Biochem Mol Biol. 2005 Jul;96(2):119-29. doi: 10.1016/j.jsbmb.2005.02.012. J Steroid Biochem Mol Biol. 2005. PMID: 15950459

8

Keeping data continuous when analyzing the prognostic impact of a tumor marker: an example with cathepsin D in breast cancer.

Bossard N, Descotes F, Bremond AG, Bobin Y, De Saint Hilaire P, Golfier F, Awada A, Mathevet PM, Berrerd L, Barbier Y, Estève J. Bossard N, et al. Among authors: descotes f. Breast Cancer Res Treat. 2003 Nov;82(1):47-59. doi: 10.1023/B:BREA.0000003919.75055.e8. Breast Cancer Res Treat. 2003. PMID: 14672403

9

Transcriptome profiling of gastric-type endocervical adenocarcinomas identifies key signaling pathways for tumor progression.

Vasseur D, Lopez J, Croce S, Tondeur G, Bonin L, Descotes F, Golfier F, Devouassoux-Shisheboran M. Vasseur D, et al. Among authors: descotes f. Gynecol Oncol. 2020 Jun;157(3):775-782. doi: 10.1016/j.ygyno.2020.04.046. Epub 2020 Apr 18. Gynecol Oncol. 2020. PMID: 32317172

10

Microarray gene expression profiling and analysis of bladder cancer supports the sub-classification of T1 tumours into T1a and T1b stages.

Descotes F, Dessen P, Bringuier PP, Decaussin M, Martin PM, Adams M, Villers A, Lechevallier E, Rebillard X, Rodriguez-Lafrasse C, Devonec M, Paparel P, Perrin P, Lazar V, Ruffion A. Descotes F, et al. BJU Int. 2014 Feb;113(2):333-42. doi: 10.1111/bju.12364. Epub 2013 Oct 31. BJU Int. 2014. PMID: 24053469

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

66 results

Search Page